At TransEnterix, our vision is to improve clinical outcomes and patient care through the use of robotics in surgery. We seek to enhance and support surgeon capabilities while reducing the barriers to adoption with responsible economics and leveraging existing laparoscopic skills.
Disruptive Technological and Economic Innovation
We believe that future growth of surgical robotics will be defined by disruptive innovation, both from a technological and economic perspective:
- Build on success of laparoscopy while addressing limitations
- Innovative technology that addresses trade-offs
- Compelling economic value to hospitals
U.S. Public Company (TRXC), Founded in 2006
TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the commercialization of the Senhance™ Surgical System, a multi-port system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The company also developed the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform. The Senhance Surgical System has been granted a CE Mark and has received clearance for sale in the United States.